Application of L-serine in the preparation of drugs that inhibit ferroptosis in testicular interstitial cells

By inhibiting ferroptosis in testicular interstitial cells through L-serine, the problem of testicular atrophy caused by SD is solved, thus maintaining testicular endocrine function and protecting reproductive function. It is suitable for use in drugs, nutritional supplements, and health foods.

CN123059031APending Publication Date: 2026-11-10NANCHANG UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202611394821.7
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2026-09-09
Publication Date
2026-11-10

AI Technical Summary

Technical Problem

Current technologies have not fully revealed the relationship between sleep deprivation (SD)-induced testicular atrophy and ferroptosis of testicular interstitial cells. There is a lack of clear targeted intervention programs, making it difficult to effectively inhibit ferroptosis of testicular interstitial cells, which leads to decreased testosterone synthesis capacity and testicular atrophy.

Method used

Using L-serine as the active ingredient, a drug intervention program was developed to prevent and improve testicular atrophy by inhibiting ferroptosis in testicular interstitial cells, reducing lipid peroxidation and iron-dependent cell damage.

Benefits of technology

It has the advantages of clearly targeting and inhibiting ferroptosis in testicular interstitial cells, maintaining testicular endocrine function, and reducing testicular atrophy and reproductive function damage. It is widely used in drugs, nutritional supplements and health foods.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN123059031A_ABST
    Figure CN123059031A_ABST
Patent Text Reader

Abstract

This invention discloses the application of L-serine in the preparation of drugs that inhibit ferroptosis in testicular interstitial cells, belonging to the field of biomedical technology. This invention discovers that L-serine can inhibit ferroptosis in testicular interstitial cells and can be used to prepare drugs for preventing and / or improving sleep deprivation-induced testicular atrophy. The drug uses L-serine as the active ingredient and can be formulated into a pharmaceutically acceptable dosage form. L-serine is a naturally occurring amino acid in the human body, exhibiting good safety and tolerability. Developing it as a drug for the prevention and treatment of diseases related to ferroptosis in testicular interstitial cells has a low risk of toxic side effects and promising clinical application prospects.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention relates to the field of biomedicine, specifically to the application of L-serine in the preparation of drugs that inhibit ferroptosis in testicular interstitial cells. Background Technology

[0002] Leydig cells are the core cell type for testicular endocrine function, primarily responsible for testosterone synthesis and secretion. Testosterone not only maintains male secondary sexual characteristics and reproductive function but also plays a crucial role in the integrity of seminiferous tubules, the function of supporting cells, and spermatogenesis. Therefore, damage to these interstitial cells can lead to decreased testosterone synthesis, further causing degenerative changes in seminiferous tubules and testicular atrophy. Recent studies have shown that various factors, including sleep deprivation (SD), oxidative stress, and exposure to exogenous toxins, can cause damage to testicular interstitial cells, leading to decreased testosterone secretion, impaired spermatogenesis, and testicular atrophy.

[0003] Ferroptosis is a regulated form of cell death distinct from apoptosis, necrosis, and autophagy, characterized by the accumulation of iron-dependent lipid peroxidation. Ferroptosis is typically accompanied by elevated levels of intracellular free iron or ferrous iron, increased lipid reactive oxygen species and lipid peroxidation products such as malondialdehyde (MDA), glutathione (GSH) depletion, and abnormal expression of ferroptosis-related factors such as HO-1 and Nrf2. In recent years, ferroptosis has been shown to participate in various organ injuries and metabolic stress processes, and is increasingly considered to be associated with reproductive system damage. However, current techniques have not fully elucidated that ferroptosis in testicular interstitial cells is a key pathological step in testicular atrophy caused by stunted growth factor (SD).

[0004] Serine, especially L-serine, is an essential amino acid naturally present in the body, participating in protein synthesis, one-carbon metabolism, nucleotide synthesis, phospholipid metabolism, glutathione synthesis, and the maintenance of cellular redox homeostasis. Ferraphobia is closely related to glutathione depletion, decreased GPX4 function, lipid peroxidation accumulation, and abnormal cell membrane lipid metabolism. Serine has the potential to influence ferrophobia by regulating metabolism and its ability to resist lipid peroxidation. However, current technologies have not disclosed or suggested the use of serine to inhibit SD-induced ferroptosis in testicular interstitial cells, nor have they disclosed its ability to prevent or improve SD-induced testicular atrophy by maintaining interstitial cell function and testosterone synthesis.

[0005] Therefore, it is necessary to develop a safe, easy-to-implement, and clearly targeted intervention program to inhibit SD-induced ferroptosis in testicular interstitial cells, maintain testicular endocrine function, and reduce seminiferous tubule structural damage and testicular atrophy. Summary of the Invention

[0006] The technical problems to be solved by this invention include: Current approaches have not fully elucidated the relationship between testicular atrophy caused by testicular dysplasia (SD) and ferroptosis in testicular interstitial cells, thus making it difficult to fundamentally halt the disease progression. Furthermore, existing techniques primarily intervene from the perspectives of general oxidative stress, inflammatory responses, or endocrine disorders, lacking a clear targeted approach addressing the core pathological mechanisms of testicular atrophy caused by SD. Currently, there is a lack of a safe, easily implemented, and effective approach that can improve testicular atrophy caused by SD by regulating interstitial cell ferroptosis.

[0007] To address the aforementioned problems, this invention provides the application of L-serine in the preparation of drugs that inhibit ferroptosis in testicular interstitial cells. This invention aims to improve testicular tissue structure and alleviate testicular weight loss by supplementing with serine, thereby inhibiting SD-induced ferroptosis in testicular interstitial cells, reducing lipid peroxidation and iron-dependent cell damage, and ultimately preventing and improving testicular atrophy and related reproductive function damage caused by SD.

[0008] The present invention achieves the above objectives through the following technical solutions: In a first aspect, the present invention provides the use of L-serine in the preparation of drugs that inhibit ferroptosis in testicular interstitial cells.

[0009] Furthermore, the testicular interstitial cell ferroptosis is sleep deprivation-induced testicular interstitial cell ferroptosis.

[0010] Furthermore, the drug is used to prevent and / or improve testicular atrophy.

[0011] Furthermore, the testicular atrophy is sleep deprivation-induced testicular atrophy.

[0012] Furthermore, L-serine is the active ingredient in the drug.

[0013] Furthermore, L-serine is the sole active ingredient in the drug.

[0014] Furthermore, the drug also comprises a pharmaceutically acceptable carrier and / or excipient.

[0015] Furthermore, the dosage form of the drug is at least one of an oral formulation, an injectable formulation, or a topical formulation.

[0016] Furthermore, the oral preparation is at least one of tablets, capsules, granules, oral liquids, or powders; the injectable preparation is at least one of intravenous injections, intramuscular injections, or subcutaneous injections.

[0017] Furthermore, the drug includes at least one function of reducing intracellular iron ion accumulation, reducing the generation of lipid reactive oxygen species and lipid peroxidation products, and reducing the expression of ferroptosis-related factors (HO-1, Nrf2, etc.).

[0018] Compared with the prior art, the present invention has the following beneficial effects: 1. This invention is the first to clearly identify the key pathological mechanism of testicular atrophy caused by sleep deprivation (SD) as ferroptosis in testicular interstitial cells, and based on this, proposes a targeted intervention program using serine, preferably L-serine, as the active ingredient. Compared with existing techniques that mainly intervene from the perspective of general oxidative stress, inflammatory response, or endocrine disorders, this invention has a clearer target and stronger mechanism specificity, and can inhibit SD-induced interstitial cell damage and its subsequent testicular atrophy from the source.

[0019] 2. The active ingredient of this invention is serine, a natural amino acid, which has advantages such as wide availability, convenient preparation, good biocompatibility, and high safety. It is suitable for development into pharmaceutical preparations, nutritional supplements, functional foods, health foods, or feed additives, with a wide range of applications and convenient implementation. Compared to some experimental ferroptosis inhibitors or iron chelators, the serine used in this invention has greater practical application and long-term intervention feasibility.

[0020] 3. This invention not only inhibits iron-dependent lipid peroxidation and intracellular iron homeostasis disorders, but also maintains testicular interstitial cell function and testosterone synthesis levels, thus achieving comprehensive effects in improving testicular weight loss, alleviating seminiferous tubule atrophy, protecting testicular tissue structure, and maintaining reproductive function. Compared with existing solutions that only partially improve oxidative stress or sperm quality, this invention has the advantages of a more complete level of action, stronger targeting, and better overall protective effect. Attached Figure Description

[0021] Figure 1 This is a preferred embodiment of the present invention for phenotypic verification of a sleep-deprived mouse model. Wherein: Figure 1 In this context, A represents the sperm motility assay in SD mice; Figure 1 B in the figure represents the detection of sperm concentration and the proportion of forward-moving sperm in SD mice; Figure 1 C in the text represents HE staining of seminiferous tubules from SD mice; Figure 1 In this context, D represents the effect of the blood-testis barrier in SD mice; Figure 1 E in the figure represents the detection of cell proliferation in testicular tissue of SD mice; Figure 1 F in the figure represents the detection of systemic inflammatory response in mice.

[0022] Figure 2 This is a schematic diagram illustrating testicular atrophy caused by SD-induced ferroptosis in testicular interstitial cells according to a preferred embodiment of the present invention. Wherein: Figure 2 In this context, A represents the change in the proportion of testicular interstitial cells after SD. Figure 2 In this context, B represents atrophy of the testicular interstitial width; Figure 2 C in the text represents a differentially expressed gene enriched in the ferroptosis pathway in testicular interstitial cells. Figure 2 D in the figure represents the detection of MDA and ferrous ion accumulation; Figure 2 E in the Venn diagram is used to identify differentially expressed genes related to ferroptosis (Hmox-1 is the most significant). Figure 2 F in the figure represents Hmox-1 expression in testicular interstitial cells as shown by immunofluorescence. Figure 2 In the figure, G represents Nrf2 expression in testicular interstitial cells as shown by immunofluorescence. Figure 2 H in the figure represents the detection of protein expression of HO-1 and Nrf2.

[0023] Figure 3 This is a schematic diagram illustrating the ameliorative effect of L-serine on sleep deprivation-induced testicular atrophy in mice. (The diagram shows...) Figure 3 In this context, A represents the improvement of testicular organ rate caused by SD after L-serine supplementation; Figure 3 The B in the formula represents L-serine supplementation to improve abnormal testosterone secretion; Figure 3 C in the figure represents the statistical results of the improvement in the width of the seminiferous tubules stained with HE and the surface area of ​​testicular tissue sections in SD mice after L-serine supplementation. Figure 3 D in the figure represents the detection of MDA and ferrous ion accumulation after L-serine supplementation; Figure 3 E in the text refers to the accumulation of ferrous ions in testicular interstitial cells after L-serine supplementation and Prussian blue staining. Figure 3 F in the figure represents the protein expression detection of Nrf2, HO-1, and Keap1. Detailed Implementation

[0024] The endpoints and any values ​​of the ranges disclosed herein are not limited to the precise ranges or values, and these ranges or values ​​should be understood to include values ​​close to these ranges or values. For numerical ranges, the endpoint values ​​of the various ranges, the endpoint values ​​of the various ranges and individual point values, and individual point values ​​can be combined with each other to obtain one or more new numerical ranges, which should be considered as specifically disclosed herein.

[0025] In one embodiment of the present invention, without departing from the inventive concept, the serine intervention scheme described herein can also employ various alternative implementation methods to achieve the same or similar technical effects. The serine is preferably L-serine, but can also be formulated into pharmaceutically or food-grade forms according to actual application needs, including but not limited to tablets, capsules, granules, powders, oral liquids, suspensions, lyophilized preparations, sustained-release preparations, drinking water additives, or feed additives. The administration method can be oral, gavage, drinking water administration, or feed mixing, to adapt to different application scenarios.

[0026] In one embodiment of the invention, serine can also be used in combination with other ingredients that have antioxidant, anti-ferroptosis, or testicular function-enhancing effects to strengthen the inhibitory effect on sleep deprivation-induced ferroptosis of testicular interstitial cells. The auxiliary ingredients may include, but are not limited to, N-acetylcysteine, vitamin E, vitamin C, zinc, selenium, taurine, coenzyme Q10, glutathione precursor, or other bioprotective nutritionally active substances. In this type of compound formulation, serine still functions as the primary active ingredient.

[0027] In one embodiment of the present invention, the application can be extended not only to human populations, but also to laboratory animals, model animals, or other subjects requiring assessment of sleep deprivation-related testicular damage. The present invention can be used for both preventative and therapeutic or ameliorative purposes; it can be used for both continuous and intermittent interventions during sleep deprivation.

[0028] The above-described alternative embodiments are all reasonable variations and equivalent substitutions of the present invention, and can all achieve similar technical effects in inhibiting sleep deprivation-induced ferroptosis of testicular interstitial cells, improving testicular atrophy, and maintaining testicular function.

[0029] The technical solution of the present invention will now be clearly and completely described with reference to the accompanying drawings. Obviously, the described embodiments are only some, not all, of the embodiments of the present invention. All other embodiments obtained by those skilled in the art based on the embodiments of the present invention without creative effort are within the scope of protection of the present invention.

[0030] Unless otherwise specified, the raw materials used in the following embodiments are all disclosed in the prior art, such as those that can be directly purchased or prepared according to the preparation methods disclosed in the prior art.

[0031] Experimental materials: All 15-week-old Balb / c mice used in this study were purchased from GemPharmatech LLC. All mice underwent a one-week acclimatization period after entering the specific pathogen-free (SPF) animal facility. For the SD group mice, a 4 cm deep water layer was created in the cages using room temperature distilled water. Based on their nocturnal activity patterns, mice were placed in platform-style drinking cages from 17:00 to 13:00 the following day, and then placed in regular cages for rest from 13:00 to 17:00. To ensure a hygienic environment for the SD group mice, the water-covered cages were changed every 24 hours, along with the feed troughs. After every four consecutive days of fasting, the mice were allowed two days of free rest, for a total fasting period of 16 days.

[0032] All animal experiments were conducted in strict accordance with the institutional guidelines (Agreement No.: NCULEA-20241004099) developed by the Laboratory Animal Welfare and Ethics Committee of Nanchang University.

[0033] Example 1: Establishment and phenotypic validation of a sleep-deprivation mouse model 1.1 Laboratory Animals and Grouping Fifteen-week-old male Balb / c mice were randomly divided into three groups (n=20 / group): - Normal control group (Control): Normal sleep, free access to food and water; - Sleep Deprivation Group (SD): A custom-designed mouse cage (50 cm long, 30 cm wide, and 20 cm high) was used to induce sleep deprivation in mice. The cage contained 20 acrylic cylinders, each 5 cm high and 4 cm in diameter. Food was supplied through connected channels, and drinking water was provided through rodent-specific water bottles with built-in nozzles. The mice were deprived for 20 hours a day (from 16:00 to 12:00 the next day) for 16 consecutive days. 1.2 Sampling and Testing During the establishment of the SD model, mouse weight, survival rate, and mortality data were recorded. On day 16, the mice were anesthetized and euthanized, and testicular tissue, blood, and sperm samples were collected for sperm motility analysis, HE staining, testicular tissue qPCR, and Western blot experiments.

[0034] 1.3 Experimental Results Sperm analysis of the testes of mice treated with SD (sperm saturation) showed that sperm motility was significantly reduced in SD mice. Figure 1 As shown in A; sperm concentration is significantly reduced, such as Figure 1 As shown in B, the number of forward-motile sperm is significantly reduced. HE staining of testicular tissue reveals disordered seminiferous tubule structure and disruption of the seminiferous epithelium hierarchy, such as... Figure 1 As shown in C.

[0035] A few studies have shown that blood-testis barrier dysfunction is a significant factor leading to male spermatogenesis disorders. Our results indicate that SD has a relatively limited impact on the blood-testis barrier, such as... Figure 1 As shown in D in the diagram. Detection of testicular tissue cell proliferation showed that SD leads to a shift in testicular tissue cells from proliferation to apoptosis, as... Figure 1 As shown in E in the figure.

[0036] The study examined inflammatory responses in mouse testicular tissue and the proportion of immune cells in the blood, which reflects systemic inflammation levels. The results showed that SD mice exhibited a systemic inflammatory response, consistent with existing literature reports. Figure 1 As shown in F in the diagram.

[0037] 1.4 Summary This embodiment successfully established a serosanguineous spermatogenesis (SD) model in 15-week-old mice, demonstrating that SD can lead to: ① a significant decrease in sperm motility, concentration, and forward motility; ② seminiferous tubule structural disorder; and ③ a systemic inflammatory response. This model provides a reliable animal experimental platform for subsequent mechanistic studies.

[0038] Example 2: SD-induced ferroptosis in testicular interstitial cells leading to testicular atrophy 2.1 Laboratory Animals and Grouping Same as Example 1.

[0039] 2.2 Sampling and Testing During the establishment of the SD model, mouse weight, survival rate, and mortality data were recorded. On day 16, the mice were anesthetized and euthanized, and testicular tissue, blood, and sperm samples were collected for experiments such as single-cell detection of testicular tissue, ferroptosis detection of testicular tissue, HE staining, and Western blot.

[0040] 2.3 Single-cell sequencing analysis of changes in the proportion of testicular interstitial cells Single-cell sequencing results showed that the proportion of interstitial cells constituting the testicular interstitium decreased significantly after SD, while the proportion of other spermatogenic cells, except for elongated spermatids, remained basically unchanged. Figure 2 (A in the text). This result indicates that testicular atrophy caused by SD is not primarily caused by a reduction in spermatogenic cells, but is closely related to the loss of testicular interstitial cells.

[0041] 2.4 Testicular interstitial width detection Testicular tissues from mice in each group were collected, dehydrated, embedded, sectioned, and stained with hematoxylin and eosin (HE). The tissues were then observed under a microscope. Results showed that SD (testicular dysplasia) led to the loss of interstitial cells in the testes, subsequently causing atrophy of the interstitial space. Figure 2 (B in the text) confirms that the absence of testicular interstitial cells leads to the destruction of the interstitial structure.

[0042] 2.5 Enrichment analysis of differentially expressed gene KEGG in testicular interstitial cells and detection of ferroptosis markers To investigate the potential mechanisms of mesenchymal cell loss caused by SD, changes in mesenchymal cell gene expression induced by SD were analyzed, revealing that ferroptosis plays a key role in this process. Figure 2 (C) Testicular tissue homogenate was taken and tested according to the instructions of the MDA kit and ferrous ion kit. The results showed that SD could lead to significant accumulation of malondialdehyde (MDA) and ferrous ions in testicular tissue. Figure 2 (D in the middle).

[0043] 2.6 Identification of key genes in ferroptosis By performing Venn diagram analysis on differentially expressed genes and genes from the ferroptosis database, five differentially expressed genes were identified, among which Hmox-1 showed the most significant differential expression. Figure 2 In addition, immunofluorescence results showed that SD significantly increased the expression level of Hmox-1 in mesenchymal cells (E). Figure 2 (F in the text).

[0044] 2.7 Keap1 / Nrf2 / HO-1 signaling pathway SD can activate the Keap1 / Nrf2 / HO-1 signaling pathway by promoting Nrf2 expression, triggering ferroptosis in testicular interstitial cells and leading to testicular atrophy. Figure 2 In G). Western blot analysis showed that SD significantly increased the expression levels of Nrf2 and HO-1 proteins in testicular interstitial cells (G). Figure 2 (H in the text).

[0045] 2.8 Summary This embodiment confirms that sleep deprivation induces ferroptosis in testicular interstitial cells by activating the Keap1 / Nrf2 / HO-1 signaling pathway (MDA accumulation, ferrous ion accumulation, increased ROS, lipid peroxidation, and upregulation of Hmox-1 / Nrf2 / HO-1), leading to a decrease in the proportion of testicular interstitial cells and atrophy of the width of the testicular interstitium, thereby causing testicular atrophy.

[0046] Example 3: L-serine supplementation inhibits testicular atrophy induced by SD 3.1 Laboratory Animals and Grouping 15-week-old male Balb / c mice were randomly divided into 3 groups (n=20 / group): - Normal control group (Control): Normal sleep, free access to food and water; - Sleep Deprivation Group (SD): A custom-designed mouse cage (50 cm long, 30 cm wide, and 20 cm high) was used to induce sleep deprivation in mice. The cage contained 20 acrylic cylinders, each 5 cm high and 4 cm in diameter. Food was supplied through connected channels, and drinking water was provided through rodent-specific water bottles with built-in nozzles. The mice were deprived for 20 hours a day (from 16:00 to 12:00 the next day) for 16 consecutive days. - Experimental group (SD+L-serine): During the SD process, L-serine (100g / L) was supplemented daily through intraperitoneal fluid intake.

[0047] 3.2 Sampling and Testing During the establishment of the SD model, mouse weight, survival rate and mortality data were recorded. On day 16, the mice were anesthetized and euthanized, and testicular tissue, blood and sperm samples were collected.

[0048] 3.3 Testicular organ rate detection After euthanizing the mice, the abdomen was dissected, and the testicular tissue from both sides was removed. The weight of both testes was recorded, and the testicular organ percentage was calculated. Testicular organ percentage (%) = (mice testicular mass / mouse body weight) × 100%.

[0049] The results showed that, compared with the model control group, L-serine supplementation during SD could inhibit SD-induced testicular atrophy. Figure 3 (A in the middle).

[0050] 3.4 Serum testosterone secretion detection Since the interstitial cells of the testis are the main system for producing testosterone, a competitive ELISA method was used to detect the level of testosterone in mouse serum.

[0051] The results showed that L-serine supplementation could inhibit the decrease in testosterone secretion caused by SD ( Figure 3 (B in the middle).

[0052] 3.5 HE staining of testicular tissue Mouse testicular tissue was dehydrated, embedded, sectioned, and stained with hematoxylin and eosin (HE). The changes in the width of the interstitial space were observed under an upright microscope, and the surface area of ​​the mouse testicular tissue sections was counted.

[0053] The results showed that L-serine supplementation during SD could increase interstitial width. Figure 3 (C in the middle).

[0054] 3.6 Testicular tissue ferroptosis detection MDA and ferrous ion accumulation are important indicators for detecting ferroptosis in animal tissues. Testicular tissue from euthanized mice was homogenized, and the MDA and ferrous ion content were analyzed according to the instructions of the MDA and ferrous ion reagent kits. Testicular tissue sections were dewaxed, dehydrated, stained with Prussian blue, and observed under an upright microscope to determine the ferrous ion content.

[0055] The results showed that L-serine supplementation significantly inhibited SD-induced ferroptosis in testicular tissue, manifested by a decrease in MDA levels ( Figure 3 D), ferrous ion level decreased ( Figure 3 (E in the text).

[0056] 3.7 Detection of Keap1 / Nrf2 / HO-1 signal pathway Mouse testicular tissue was homogenized and lysed to obtain protein solutions, which were then analyzed by Western blot to detect the expression of Keap1, Nrf2, and HO-1 proteins.

[0057] The results showed that SD activated the Keap1 / Nrf2 / HO-1 signaling pathway in testicular tissue; L-serine supplementation inhibited the activation of this signaling pathway. Figure 3 (F in the text).

[0058] 3.8 Summary This embodiment confirms that L-serine supplementation can ① inhibit testicular atrophy and increase interstitial width caused by sleep deprivation (SD); ② inhibit the decrease in testosterone secretion caused by SD; ③ significantly inhibit ferroptosis in testicular tissue caused by SD (reduced accumulation of MDA and ferrous ions); and ④ inhibit the activation of the Keap1 / Nrf2 / HO-1 signaling pathway. These results indicate that L-serine plays a role in preventing and treating testicular atrophy caused by sleep deprivation by inhibiting ferroptosis in testicular interstitial cells mediated by the Keap1 / Nrf2 / HO-1 pathway.

[0059] The above description is merely a preferred embodiment of the present invention, and the present invention is not limited to the above embodiments. It is understood that other improvements and variations that are directly derived or conceived by those skilled in the art without departing from the spirit and concept of the present invention should be considered to be included within the protection scope of the present invention.

Claims

1. Application of L-serine in the preparation of drugs that inhibit ferroptosis in testicular interstitial cells.

2. The application according to claim 1, characterized in that, The testicular interstitial cell ferroptosis mentioned is sleep deprivation-induced testicular interstitial cell ferroptosis.

3. The application according to claim 1, characterized in that, The drug is used to prevent and / or improve testicular atrophy.

4. The application according to claim 3, characterized in that, The testicular atrophy mentioned is sleep deprivation-induced testicular atrophy.

5. The application according to claim 1, characterized in that, L-serine is the active ingredient in the drug.

6. The application according to claim 5, characterized in that, L-serine is the only active ingredient in the drug.

7. The application according to claim 1, characterized in that, The drug also includes a pharmaceutically acceptable carrier and / or excipient.

8. The application according to claim 1, characterized in that, The dosage form of the drug is at least one of oral preparations, injectable preparations, or topical preparations.

9. The application according to claim 8, characterized in that, The oral preparation is at least one of tablets, capsules, granules, oral liquids, or powders; the injectable preparation is at least one of intravenous injections, intramuscular injections, or subcutaneous injections.

10. The application according to claim 1, characterized in that, The drug includes at least one function of reducing intracellular iron accumulation, reducing the generation of lipid reactive oxygen species and lipid peroxidation products, and reducing the expression of ferroptosis-related factors.